Lars Fruergaard Jørgensen Joins the ZymoGenetics Board of Directors
June 18, 2010
SEATTLE, Jun 18, 2010 (BUSINESS WIRE) --ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced that Lars Fruergaard Jørgensen of Novo Nordisk A/S was elected to the company's Board of Directors at the annual meeting of shareholders. He replaces Lars Rebien Sørensen, a previous Novo Nordisk representative, who resigned from the Board in March 2010. Novo Nordisk holds approximately 27% of the company's outstanding shares.
"Lars Fruergaard Jørgensen brings to our Board many years of operational, financial and strategic experience in the global pharmaceutical industry," said Bruce L.A. Carter, Ph.D., Chairman of the Board of ZymoGenetics. "We look forward to his participation and contribution in the coming years."
Lars Fruergaard Jørgensenhas served as Senior Vice President, Information Technology and Corporate Development of Novo Nordisk A/S since September 2004. From 2001 to 2004, he served as Vice President, Regional Finance and Information Technology of Novo Nordisk Pharmaceutical Ltd. with responsibility for a region comprising Japan and Oceania. He joined Novo Nordisk in 1991 and has held positions of increasing responsibility within the finance, accounting and administration departments. He currently serves, or has during the past five years served, as a director of NNIT A/S and as chairman of the board of Harno Invest A/S. Mr. Jørgensen received a B.Sc. and M.Sc. in Business Administration from the Århus Business School, Denmark.
ZymoGenetics is a biopharmaceutical company focused on the development and commercialization of therapeutic proteins for the treatment of human diseases. The company has developed and is marketing RECOTHROM(R) Thrombin, topical (Recombinant) in the United States. ZymoGenetics has two product candidates in Phase 2 clinical development: PEG-Interferon lambda, being studied in collaboration with Bristol Myers Squibb (BMS) for treatment of hepatitis C virus (HCV) infection, and IL-21, being tested by ZymoGenetics as a potential treatment for metastatic melanoma. In addition, ZymoGenetics has an anti-IL-31 monoclonal antibody in preclinical development, which it expects to test initially as a treatment for atopic dermatitis. Several of the product candidates previously identified through ZymoGenetics' discovery research efforts have been licensed to and are being developed by third parties, including Merck Serono and Novo Nordisk. ZymoGenetics is eligible to receive milestone payments and royalties related to these assets. For further information, visit www.zymogenetics.com.
SOURCE: ZymoGenetics, Inc.
ZymoGenetics, Inc.Media and Investor RelationsSusan W. Specht, 206-442-6592